A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
Latest Information Update: 18 Sep 2024
At a glance
- Drugs Ferumoxytol (Primary) ; Iron sucrose
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Sponsors AMAG Pharmaceuticals
Most Recent Events
- 12 Aug 2024 Planned End Date changed from 31 Aug 2023 to 31 Aug 2024.
- 12 Aug 2024 Planned primary completion date changed from 31 Aug 2023 to 31 Aug 2024.
- 18 Jul 2023 Planned primary completion date changed from 31 Mar 2023 to 31 Aug 2023.